Cargando…
Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy
Colon cancer is one of the most common gastrointestinal tumors in the world. Currently, the commonly used methods such as radiotherapy, chemotherapy and drug treatments are often ineffective and have significant side effects. Here we developed a safe and efficient biomaterials based anti-tumor nanop...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127421/ https://www.ncbi.nlm.nih.gov/pubmed/35620794 http://dx.doi.org/10.1016/j.mtbio.2022.100294 |
_version_ | 1784712350244274176 |
---|---|
author | Zhang, Long Zhang, Wan Peng, Hang Shen, Tianli Wang, Min Luo, Meng Qu, Xiaoyan Qu, Fengyi Liu, Wenguang Lei, Bo Yang, Shuanying |
author_facet | Zhang, Long Zhang, Wan Peng, Hang Shen, Tianli Wang, Min Luo, Meng Qu, Xiaoyan Qu, Fengyi Liu, Wenguang Lei, Bo Yang, Shuanying |
author_sort | Zhang, Long |
collection | PubMed |
description | Colon cancer is one of the most common gastrointestinal tumors in the world. Currently, the commonly used methods such as radiotherapy, chemotherapy and drug treatments are often ineffective and have significant side effects. Here we developed a safe and efficient biomaterials based anti-tumor nanoplatform (M@NPs/miR365), which was formed with poly (citrate-peptide) (PCP), miRNA365 mimic and MC38 cancer cell membrane (M). PCP could efficiently deliver miR365 mimic into MC38 cancer cells, promote the apoptosis of MC38 tumor cells and regulate the expression of Bcl2 and Ki67 in vitro. Tumor cell membranes were prepared by a fast and convenient sonication method. This tumor cell membrane-coated drug delivery system M@NPs can effectively reduce macrophage uptake and increase the stability of NPs. And the MC38 tumor model mice experiment showed that M@NPs/miR365 via caudal vein injection effectively inhibit tumor development. Based on the immune escape and homologous targeting of cancer cells and efficient gene transfection ability of NPs, this “Trojan horse” like “Pseudotumor cell” carries the target gene miR365 mimic to the tumor site and realizes cancer therapy. Noteworthy, the drug delivery system has good biocompatibility. Thus, this safe drug delivery strategy mediated by cancer cell membrane and gene therapy may have a certain significance for reducing the gap between nanoplatform and tumor clinical treatment. |
format | Online Article Text |
id | pubmed-9127421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91274212022-05-25 Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy Zhang, Long Zhang, Wan Peng, Hang Shen, Tianli Wang, Min Luo, Meng Qu, Xiaoyan Qu, Fengyi Liu, Wenguang Lei, Bo Yang, Shuanying Mater Today Bio Full Length Article Colon cancer is one of the most common gastrointestinal tumors in the world. Currently, the commonly used methods such as radiotherapy, chemotherapy and drug treatments are often ineffective and have significant side effects. Here we developed a safe and efficient biomaterials based anti-tumor nanoplatform (M@NPs/miR365), which was formed with poly (citrate-peptide) (PCP), miRNA365 mimic and MC38 cancer cell membrane (M). PCP could efficiently deliver miR365 mimic into MC38 cancer cells, promote the apoptosis of MC38 tumor cells and regulate the expression of Bcl2 and Ki67 in vitro. Tumor cell membranes were prepared by a fast and convenient sonication method. This tumor cell membrane-coated drug delivery system M@NPs can effectively reduce macrophage uptake and increase the stability of NPs. And the MC38 tumor model mice experiment showed that M@NPs/miR365 via caudal vein injection effectively inhibit tumor development. Based on the immune escape and homologous targeting of cancer cells and efficient gene transfection ability of NPs, this “Trojan horse” like “Pseudotumor cell” carries the target gene miR365 mimic to the tumor site and realizes cancer therapy. Noteworthy, the drug delivery system has good biocompatibility. Thus, this safe drug delivery strategy mediated by cancer cell membrane and gene therapy may have a certain significance for reducing the gap between nanoplatform and tumor clinical treatment. Elsevier 2022-05-17 /pmc/articles/PMC9127421/ /pubmed/35620794 http://dx.doi.org/10.1016/j.mtbio.2022.100294 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Full Length Article Zhang, Long Zhang, Wan Peng, Hang Shen, Tianli Wang, Min Luo, Meng Qu, Xiaoyan Qu, Fengyi Liu, Wenguang Lei, Bo Yang, Shuanying Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy |
title | Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy |
title_full | Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy |
title_fullStr | Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy |
title_full_unstemmed | Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy |
title_short | Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy |
title_sort | bioactive cytomembrane@poly(citrate-peptide)-mirna365 nanoplatform with immune escape and homologous targeting for colon cancer therapy |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127421/ https://www.ncbi.nlm.nih.gov/pubmed/35620794 http://dx.doi.org/10.1016/j.mtbio.2022.100294 |
work_keys_str_mv | AT zhanglong bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT zhangwan bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT penghang bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT shentianli bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT wangmin bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT luomeng bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT quxiaoyan bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT qufengyi bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT liuwenguang bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT leibo bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy AT yangshuanying bioactivecytomembranepolycitratepeptidemirna365nanoplatformwithimmuneescapeandhomologoustargetingforcoloncancertherapy |